Healthcare Industry News: BOTOX
News Release - September 26, 2006
Allergan, Inc. Announces Launch of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUSIRVINE, Calif.--(HSMN NewsFeed)--Allergan, Inc. (NYSE:AGN ), the maker of BOTOX® Cosmetic (Botulinum Toxin Type A), today announced it is launching its 'next-generation' hyaluronic acid dermal filler products, JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS, through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January 2007. Allergan will begin accepting physician pre-orders for the products on November 1, 2006 via its nationwide sales force.
"We are pleased to announce the availability of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS as they join BOTOX® Cosmetic and our physician-dispensed skincare treatments in Allergan's facial aesthetics portfolio," said Robert Grant, Allergan Corporate Vice President and President of Inamed, a division of Allergan. "We believe the unique scientific benefits of JUVEDERM(TM), along with its technologically advanced smooth formulation will establish the brand as a leader alongside BOTOX® Cosmetic in Allergan's Total Facial Rejuvenation(TM) offering."
The JUVEDERM(TM) experience trial is a multi-center, open-label trial, designed to gain relevant information on physicians' use of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS and evaluate the persistence of and patient satisfaction with the products in daily clinical practice.
"Many physicians have been awaiting the availability of the JUVEDERM(TM) family of dermal fillers," continued Mr. Grant. "As a market leader devoted to the Science of Facial Aesthetics(TM), it is our responsibility to provide our customers with the appropriate scientific and clinical information on the product to ensure optimal patient outcomes."
Physicians and consumers are encouraged to visit www.JuvedermComingSoon.com to receive additional information and announcements about JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS. Pricing of both products will be announced to physicians via the Allergan sales force starting November 1, 2006.
The U.S. Food and Drug Administration approved the JUVEDERM(TM) dermal filler family of products in June 2006. JUVEDERM(TM) ULTRA is a highly cross-linked formulation for more versatility in contouring and volumizing of facial wrinkles and folds; JUVEDERM(TM) ULTRA PLUS is a more highly cross-linked robust formulation for volumizing and correction of deeper folds and wrinkles. Both products provide a smooth, long-lasting correction of facial wrinkles and folds due to the proprietary, technologically advanced formulations that contain the highest concentration of non-animal hyaluronic acid and the highest concentration of cross-linked hyaluronic acid of any dermal filler currently available. These unique attributes provide optimal results with a single treatment in the majority of patients and deliver sustained results for up to six months or longer.
Like BOTOX® Cosmetic, JUVEDERM(TM) dermal fillers should only be administered by a trained and qualified health care provider. Further product and prescribing information is available by visiting www.JuvedermComingSoon.com and www.BOTOXCosmetic.com.
Important JUVEDERM(TM) Dermal Filler Safety Information
In clinical studies, adverse events were usually mild to moderate in nature, did not require intervention and lasted seven days or less. The most common side effects included temporary injection site reactions including redness, pain/tenderness, firmness, swelling, lumps and bumps and bruising. For complete patient safety information, please visit www.JuvedermComingSoon.com.
About Allergan, Inc.
With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc., with headquarters in Irvine, California, discovers, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.
This press release contains "forward-looking statements", including the statements by Mr. Grant, statements regarding research and development outcomes, efficacy, market and product potential and other statements regarding BOTOX® Cosmetic and JUVEDERM(TM) dermal fillers. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients and the potential for product failures; unknown risks associated with the investigational devices that are the subject of Allergan's clinical trials; potential difficulties in manufacturing new products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.
Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2005 Form 10-K and Allergan's Form 10-Q for the quarter ended June 30, 2006. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.